Grifols SA (GRLSbn.MC)
24.70EUR
1 Aug 2013
€0.61 (+2.53%)
€24.09
€24.09
€24.95
€24.02
69,783
47,732
€24.95
€15.19
About
Overall
| Beta: | 0.47 |
| Market Cap (Mil.): | €9,905.15 |
| Shares Outstanding (Mil.): | 343.78 |
| Dividend: | 0.20 |
| Yield (%): | 0.63 |
Financials
| GRLSbn.MC | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 37.97 | 37.93 | 37.76 |
| EPS (TTM): | 0.84 | -- | -- |
| ROI: | 5.52 | 19.48 | 18.76 |
| ROE: | 15.40 | 20.17 | 19.59 |
Spain's Grifols H1 net profit up 37 pct
MADRID, July 31 - Spanish pharmaceutical company Grifols, the world's third-largest blood products maker, said on Wednesday net profit rose 37 percent in the first half from a year earlier to 182.8 million euros ($242 million), boosted by overseas sales, especially in the United States.
Update-Moody's Moody's upgrades Grifols S.A. to Ba2, and senior secured /unsecured instruments to Ba1 and B1 respectively. Outlook is stable
Grifols S.A. (Grifols)
Grifols signs deal to license Aradigm's Pulmaquin
MADRID, May 21 - Spanish drugmaker Grifols said on Tuesday it has signed an exclusive contract to license U.S. Aradigm Corporation's Pulmaquin compound and may take a stake in the California-based firm.
Spain's Grifols says Q1 net profit up 19 pct y/y
MADRID, May 2 - Spanish pharmaceutical company Grifols said on Thursday net profit rose 19 percent in the first quarter of 2013 from a year earlier to 115.7 million euros ($152.6 million), boosted by overseas sales, especially Latin America and Asia.
Spain's Grifols reports fivefold increase in 2012 profit
MADRID, Feb 28 - Spanish pharmaceutical company Grifols reported a more than fivefold rise in full-year profit for 2012 to 257 million euros ($336.90 million), buoyed by its acquisition of U.S. firm Talecris last June and its wide geographic presence outside its depressed home market.

Estimates